跳至主要内容
临床试验/JPRN-UMIN000027425
JPRN-UMIN000027425已完成2 期

The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting - The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women

Kyoto Prefectural Universuty of Medicine0 个研究点目标入组 100 人开始时间: 2017年5月23日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20months-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Diagnosis of clinical or radiological disant metastasis before inclusion 2) Invasive bilateral breast cancer 3) Received prior treatment with intravenous bisphosphonates within the past 12 months 4) Following diseases which may interfere with DXA scan such as severe scoliosis, vertebral diseases 5) Current active dental problems including infection of the teeth or jawbone. Recent (within 6 weeks) or planned dental or jaw surgery(e.g., extraction, implants) 6) Other conditions judged as inappropriate for the study by the investigator

研究者

发起方
Kyoto Prefectural Universuty of Medicine

相似试验

The efficacy of the use of denosumab in the... | 临床试验